{"url_path":"/sec/aard/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1774857/0001193125-26-344978-index.html","accession_number":"0001193125-26-344978","cik":"0001774857","ticker":"AARD","issuer_name":"Aardvark Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1774857/0001193125-26-344978-index.html","primary_entity_key":"0001774857","primary_entity_name":"Aardvark Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the second quarter ended June 30, 2026, and providing business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing."}